With the development of synthetic biology, synthetic gene circuits have shown great applied potential in medicine, biology, and as commodity chemicals. An ultimate challenge in the construction of gene circuits is the lack of effective, programmable, secure and sequence-specific gene editing tools. The clustered regularly interspaced short palindromic repeat (CRISPR) system, a CRISPR-associated RNA-guided endonuclease Cas9 (CRISPR-associated protein 9)-targeted genome editing tool, has recently been applied in engineering gene circuits for its unique properties-operability, high efficiency and programmability. The traditional single-targeted therapy cannot effectively distinguish tumour cells from normal cells, and gene therapy for single targets has poor anti-tumour effects, which severely limits the application of gene therapy. Currently, the design of gene circuits using tumour-specific targets based on CRISPR/Cas systems provides a new way for precision cancer therapy. Hence, the application of intelligentized gene circuits based on CRISPR technology effectively guarantees the safety, efficiency and specificity of cancer therapy. Here, we assessed the use of synthetic gene circuits and if the CRISPR system could be used, especially artificial switch-inducible Cas9, to more effectively target and treat tumour cells.
| INTRODUC TI ON
Over the past decade, advances in synthetic biology and bioinformatics have been made in the design of reasonable and efficient artificial gene signalling circuits with desired functionality. 1 Artificial gene circuits were first constructed in prokaryotic cells and gradually implemented in eukaryotic cells. [2] [3] [4] Currently, signal networks within living organisms and cells can be reprogrammed to alter the original oncogenic signalling pathway. 5 
| The concept and composition of artificial genetic circuits
With progress in human genome sequencing research, logical relationships between related genes and their products and clarification of gene expression regulation have advanced, but studies remain to be done. 6 Simple genetic circuits consist of elements such as a promoter sequence, coding sequence, terminator, transcription factors and ribosome sites that are based on known cellular relationships, 7 because all cells use their genetic circuitry ultimately to regulate their behaviour and their reactions to the environment.
Biological technology industries have undergone unprecedented changes in the field of precision tumour treatments. It is now possible to edit the genome through integration of its components and modules. Artificial genetic circuits can connect different genes to complete a specific biological function, and generally include three functional modules, sensors, processors and actuators. 8 Sensors measure the cellular information and transmit this to the processors. . Therefore, the transcriptional activation domain (AD) fused with the CRY2 protein is carried to the specified region and promotes the expression of downstream genes. C, Schematic process of the light-inducible CRISPR dCas9. The dCas9 is split into two fragments lacking nuclease activity, and the dCas9 fragments are fused with light-inducible dimerization domains (pMag and nMag). Blue light stimulation induces heterodimerization between pMag and nMag, which enables split dCas9 fragments to reassociate, thereby reconstituting RNAguided nuclease activity. D, Schematic diagram of a small molecular artificial switch system. The combination of doxycycline and reverse tetracycline transcriptional activator (rtTA), results in changes in the conformation of rtTA, and the combination of activated rtTA and Tetresponsive element (TRE) results in the expression of target genes, such as Cas9 gene DNA, resulting in double-stranded DNA breaks (DSBs), which then insert or delete target genes by a homology-directed repair pathway (HDR) or a non-homologous end-joining pathway (NHEJ).
Furthermore, a dead-Cas9 (dCas9) was obtained by mutation of two sites, D10A and H841A, in the Cas9 gene. 24 The dCas9 can inhibit or activate the expression of target genes through the fusion expression of the functional domain of transcriptional inhibitors or activators. [25] [26] [27] [28] [29] Figure 1 illustrates the process of gene editing by Cas9 protein. Figure 2 ). The use of artificial, switchable systems promoted the safety of gene therapy, but the devices that perceive internal signal proteins will be the next generation of gene therapy tools.
| ARTIFI CIAL G ENE CIRCU ITRY BA S ED ON CRIS PR /C A S TECHNOLOGY

| CRISPR dcas9-mediated signal conductors
In recent years, several artificial synthetic elements have been de- 
| Simultaneous multi-gene regulation based on CRISPR Cas9 technology
Compared with traditional gene editing tools, such as transcription activator-like effector nucleases (TALENs) and zinc-finger nucleases (ZFNs), CRISPR Cas9 technology is not only efficient and convenient but also has an ability to regulate multiple targets simultaneously within single cell. 47 The dCas9 protein fused with transcriptional repressing or transcriptional activating domains were used to downregulate or upregulate specific single genes.
What's more, with the maturity of CRISPR technology, the multigene targeted tandem sgRNA array was also designed to regulate the expression of multiple genes simultaneously. 25 However, genes always play an important role in the growth and development of tumour cells, but the function of genes is complex and volatile, therefore, different regulatory modalities need to be chosen for different genes.
The exciting advantage of CRISPR/Cas is its ability to control multiple endogenous genes with optional ways within a single cell.
It provides only one regulatory method when dCas9 directly fused
with one transcription-related domain (ie, activation or repression).
However, previous studies 29 have shown that sgRNA can recruit different transcription-related domains and thus has the ability to upregulate and downregulate different genes simultaneously. RNAbinding proteins are used to carry the corresponding transcriptionrelated domain and specifically bind to the RNA hairpin structures.
After the fusion of different RNA hairpin structures and sgRNA, the corresponding genes can be transcriptionally activated or suppressed. This technology has provided the prospect of broad application and great application value for precise treatment of cancer cells, and has provided more possibilities for biomedical science.
| Engineering cell signalling based on the novel CRISPR dCpf1 technology
Although CRISPR Cas9 technology has played a significant role in the precise treatment of tumours, the method of delivery to the target cell remains a problem. The size of the spCas9 gene is about 4.2 kb, which is the most widely used in biology. However, system. [50] [51] [52] However, the gene editing efficiency of miniaturized CRISPR tools may be far less than that of wild-type spCas9 and
CRISPR from Prevotella and Francisella 1 (Cpf1, also named Cas12a).
Recently, a novel gene editing system has been developed for eukaryotic cells based on CRISPR dCpf1. 53 Cpf1 is a smaller protein than Cas9, and it may be easily packaged for delivery. The dead Cpf1
(dCpf1) is produced by mutation of Cpf1, which has great application value to signal amplification and transcriptional regulation of genome editing. It is also possible to construct a CRISPR-AAV integrated system by optimizing the relevant regulatory elements of dCpf1. This would greatly improve the application value of intelligentized gene circuits in future accurate cancer therapy.
| THE APPLI C ATI ON OF G ENE CIRCU ITS IN G ENE THER APY FOR C AN CER CELL S
The occurrence of cancer is closely related to the disorder of gene that gene expression regulation is neither isolated nor single, but mutually restricted and interrelated. 6 The occurrence and development of cancer cells is a complex process, which involves complex information networks interacting with many signalling molecules. 
| CHALLENG E S AND LIMITATI ON S OF THE G ENE CIRCU ITS BA S ED ON CRIS PR / C A S9 TECHNOLOGY
| The limitations of gene circuit technology
The application of gene circuits is of great significance for the precise treatment of tumours. However, there are still many deficiencies in this technology, as well as several crucial problems and technical challenges that must be solved. First, the development of tumours is a complex process involving complicated information networks that interact with multiple signalling molecules. 20 design such functional elements has become a basic challenge for the synthetic gene circuit field. 58 Therefore, it is important to correct the insufficiencies of the currently used gene circuits.
| The challenge of CRISPR Cas9 technology
It is usually fused with transcriptional activators (VPR) or transcriptional repressors (KRAB) to enhance the function when dCas9
protein exerts its transcription activation or transcription inhibition. The size of dCas9-VPR/KRAB is larger than the existing virus carrier capacity; therefore, it is a difficult problem to load into an 
| CON CLUS I ON S AND PROS PEC TS
With the development of genome editing, gene circuit technology has become more precise and demanding. 65, 66 We conducted a systematic review of gene circuit development based on CRISPR technology and summarized the applications of gene circuits in tumour treatments.
Based on existing studies, the potential application value of intelligentized gene circuits in the field of tumour gene therapy was proposed.
There are limitations in traditional gene circuit technology, including the ability to specifically differentiate tumour cells from normal cells.
Scientists have developed a series of efficient and targeted transcription factor components based on CRISPR technology. These novel designs extend the toolbox of gene editing, and enable the construction of intelligentized gene circuits, such as logic gates, 9 signal conductors, 45 analogue computing circuits, 10 counters and memory devices.
11,12
Despite CRISPR technology being widely used in synthetic biology and biomedicine, there are still limitations. The off-target effects remain a major concern, and scientists have been working on various ways to solve this problem. 19, 67, 68 For example, three neutral amino acids (alanine) were used to replace positively charged amino acids (K848A/K1003A/R1060A or K810A/ K1003A/R1060A) at their corresponding positions in the dCas9 protein, in order to reduce the non-specific binding of dCas9 to DNA (with a negative charge). 69 In addition, a truncated sgRNA with only 17-19 nucleotides was constructed for targeted DNA sequences. 70 Another major problem is that CRISPR systems are difficult to package using AAVs. Therefore, novel transcriptional activators (TFs) and transcriptional inhibitors were used, such as the dCpf1 system, a miniaturized CRISPR dCas9 system. With the development of these technologies, the CRISPR/Cas system may become more sophisticated and efficient for use in the future.
In conclusion, with the continuous development of genome editing and gene circuit technology, the abovementioned deficiencies will eventually be resolved. This will provide a method for its application in clinical treatment. Intelligentized gene circuits based on CRISPR technology will be an important research direction in the field of tumour gene therapy in the future.
